IFRX Stock News & Analysis | Latest Updates

InflaRx Announces Participation in September Investor Conferences

JENA, Germany, Aug. 21, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in two investor conferences in September 2025. Details are as follows:

August 21, 2025Conference

IFRX News

InflaRx Announces Participation in September Investor Conferences

InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update

Oppenheimer Maintains Outperform on InflaRx, Lowers Price Target to $3

InflaRx Ends Lead Asset Development After Failed Study For Rare And Painful Skin Disease

InflaRx Halts Vilobelimab Phase 3 Trial In Pyoderma Gangrenosum After Futility Finding In Interim Analysis

Oppenheimer Initiates Coverage On InflaRx with Outperform Rating, Announces Price Target of $6

InflaRx Q1 EPS $(0.14) Beats $(0.19) Estimate

Preview: InflaRx's Earnings

Cantor Fitzgerald Initiates Coverage On InflaRx with Overweight Rating, Announces Price Target of $10

Guggenheim Maintains Buy on InflaRx, Raises Price Target to $10

HC Wainwright & Co. Reiterates Buy on InflaRx, Maintains $8 Price Target

InflaRx's Cash, Cash Equivalents, And Marketable Securities Were €55.2M As Of December 31, 2024, Additional €28.7 Million (~$30M) In Gross Proceeds Subsequently Raised By An Underwritten Public Offering Extending Cash Runway Into 2027

HC Wainwright & Co. Reiterates Buy on InflaRx, Maintains $8 Price Target

Reported Earlier, InflaRx Prices $30M Public Offering: 8.25M Shares At $2.00 Each, And Pre-Funded Warrants

InflaRx Announces Public Offering Of Ordinary Shares And Pre-Funded Warrants; No Size Or Amount Disclosed

InflaRx Receives European Commission Approval For GOHIBIC For The Treatment Of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome

HC Wainwright & Co. Reiterates Buy on InflaRx, Maintains $8 Price Target

InflaRx Doses First Patient In Phase 2a Basket Study In Chronic Spontaneous Urticaria And Hidradenitis Suppurativa, Investigating Oral C5aR Inhibitor, INF904

HC Wainwright & Co. Reiterates Buy on InflaRx, Maintains $8 Price Target

InflaRx shares are trading higher after the company announced CHMP of the European Medicines Agency recommended the marketing authorization of Gohibic for the treatment of adult patients with Sars-cov-2-inducted acute respiratory distress syndrome.

InflaRx Says CHMP of European Medicines Agency Recommends Marketing Authorization Of Gohibic (Vilobelimab) Under Exceptional Circumstances For Treatment Of Adult Patients With Sars-cov-2-induced Acute Respiratory Distress Syndrome Receiving Systemic Corti

InflaRx Announced Vilobelimab Phase III Results in Critically Ill COVID-19 Patients Published in The Lancet Respiratory Medicine